Protein Kinase Inhibitors: all 15,766 studies that test it

Page 14 of 158. Open to participants first (2,605), then studies with results posted, then the rest; newest registration first within each.

• The Treatment of Ocular Adnexal Extranodal Marginal Zone B-cell Lymphoma by Orelabrutinib and RadiotherapyRecruitingNCT06503276Phase 2
• Study of Cabozantinib With Selumetinib for Plexiform NeurofibromasRecruitingNCT06502171Phase 1
• Cardiovascular Genistein Therapy for Heart Failure InflammationRecruitingNCT06501768Phase 1/2
• A Study to Evaluate the Efficacy and Safety of Frexalimab, Brivekimig, or Rilzabrutinib in Participants Aged 16 to 75 Years With Primary Focal Segmental Glomerulosclerosis or Minimal Change DiseaseRecruitingNCT06500702Phase 2
• Testing the Addition of an Anti-cancer Drug, Abemaciclib, to the Usual Chemotherapy Treatment (Gemcitabine) for Soft Tissue SarcomaRecruitingNCT06498648Phase 1/2
• Adjuvant Treatment of Patients With High Risk of Recurrent Hepatocellular Carcinoma With Donafenib in Combination With EnvafolimabRecruitingNCT06498622Phase 2
• A Randomized, Controlled, Open-label, Multicenter Clinical Trial Comparing the Efficacy and Safety of a Precision Treatment Regimen Based on Clinical-molecular Phenotypes with a Conventional Treatment Regimen in the Treatment of Patients with Active Takayasu's ArteritisRecruitingNCT06498089Phase 4
• Donafenib Combined With Immunotherapy and Local Therapy for Unresectable Hepatocellular Carcinoma That Has Failed in Previous TherapyNot yet recruitingNCT06496815Phase 4
• Bendamustine and Rituximab With or Without Orelabrutinib in MCL TreatmentRecruitingNCT06496308Phase 3
• The Real World Study of Pyrotinib in the Treatment of Advanced Breast Cancer With HER2 PositiveNot yet recruitingNCT06495541Not applicable
• Defactinib, Avutometinib and Nivolumab for the Treatment of Anti-PD1 Refractory LKB1-Mutant Advanced Non-Small Cell Lung CancerRecruitingNCT06495125Phase 2
• A Study of Elacestrant Versus Standard Endocrine Therapy in Women and Men With ER+,HER2-, Early Breast Cancer With High Risk of RecurrenceRecruitingNCT06492616Phase 3
• A Study To Evaluate The Effect Of Rifampicin Or Ltraconazole On Pharmacokinetics Of Ensartinib In Healthy VolunteersNot yet recruitingNCT06492525Phase 1
• A Phase 2 Open-label Single-arm Trial of JAK1 Inhibitor for the Treatment of Large Inflammatory Hepatocellular AdenomasRecruitingNCT06490757Phase 2
• Trilaciclib Prevents Myelosuppression With ChemoradiotherapyRecruitingNCT06490081Phase 2
• Avutometinib and Defactinib in Diffuse Gastric CancerRecruitingNCT06487221Phase 2
• Analysis of the Effectiveness and Safety of Lorlatinib in Untreated ALK-Positive NSCLC Patients in a French Real-World ContextRecruitingNCT06487078Not applicable
• EGFR-mutated Lung Cancer in Randomized Investigator-Initiated StudyRecruitingNCT06486142Phase 3
• Fruquintinib and Pirfenidone in Combination With Anti-PD-1 Antibody in Advanced or Metastatic pMMR/MSS Colorectal CarcinomaRecruitingNCT06484153Phase 2
• Furmonertinib Combined With Anlotinib in Lung Adenocarcinoma Patients With EGFR Mutations and Brain MetastasesNot yet recruitingNCT06483672Phase 2
• Basal-like PDAC Treated With Gemcitabine, Erlotinib, and Nab-paclitaxelRecruitingNCT06483555Phase 1/2
• A Study of Adebrelimab Combined With Apatinib Mesylate and Chemotherapy for Neoadjuvant Therapy and Biomarker Analysis in Limited-stage Small Cell Lung CancerRecruitingNCT06483282Phase 2
• Efficacy of Organoid-Based Drug Screening to Guide Treatment for Locally Advanced Thyroid CancerRecruitingNCT06482086Phase 2
• T-DM1 Combined With CDK4/6 Inhibitor RibociclibEnrolling by invitationNCT06481956Phase 2
• Efficacy and Safety of TKI Combined With Chemotherapy and Sequential CAR-T Cells in ND Adult Patients With Ph+ ALLRecruitingNCT06481228Not applicable
• Adebrelimab Plus Apatinib for Maintenance Therapy of Extensive Stage Small Cell Lung CancerRecruitingNCT06480864Not applicable
• RCT of Nintedanib in Fibrotic SarcoidosisRecruitingNCT06479603Phase 4
• Backline Treatment of Advanced Hepatocellular Carcinoma With PalbociclibRecruitingNCT06478927Not applicable
• A Practical Clinical Study Comparing the Fixed-cycle Regimen Containing Orelabrutinib With BTKi MonotherapyNot yet recruitingNCT06476899Phase 2
• Belumosudil to Block Chronic Lung Allograft Dysfunction (CLAD) in High Risk Lung Transplant RecipientsRecruitingNCT06476132Phase 2
• SRT Combined With Anlotinib for the Treatment of Brain Metastases From Non-small Cell Lung CancerRecruitingNCT06476093Not applicable
• Study of Targeted Therapy vs. Chemotherapy in Patients With Thyroid CancerRecruitingNCT06475989Phase 3
• Anlotinib Hydrochloride Capsules Combined With TQB2450 in the Treatment of Endometrial CancerNot yet recruitingNCT06475599Phase 3
• Efficacy of Pyrotinib Plus Capecitabine in HER2-positive MBC With Active Brain Metastases That Have Failed ADCsNot yet recruitingNCT06475443Phase 2
• Zanubrutinib and G-CHOP in Untreated Intermediate-high Risk Follicular LymphomaNot yet recruitingNCT06474481Phase 2
• Everolimus 5 mg vs 10 mg/Daily for Patients With Neuroendocrine TumorsRecruitingNCT06472388Phase 2
• Combination of Zanubrutinib, Rituximab and Venetoclax in Patients With Previously Untreated Follicular LymphomaRecruitingNCT06471738Phase 2
• Palliative Hepatectomy Combined With Targeted Therapy and Immunotherapy for Advanced Hepatocellular CarcinomaRecruitingNCT06470256Phase 1
• A Clinical Study of TQB2450 Combined With Anlotinib in Limited-Stage Small Cell Lung Cancer PatientsNot yet recruitingNCT06469879Phase 3
• Polatuzumab Vedotin and Zanubrutinib Plus R-CHP for Patients With Newly Diagnosed Untreated Non-GCB DLBCLEnrolling by invitationNCT06468943Phase 2
• Pirtobrutinib (LOXO-305) and Venetoclax for the Treatment of Patients With CLL or SLL Resistant to Covalent BTKiRecruitingNCT06466122Phase 2
• Efficacy and Safety of Dupilumab in Combination With Tofacitinib in Moderate to Severe Adult AD PatientsNot yet recruitingNCT06465732Phase 4
• Sonrotoclax, Zanubrutinib and CD20mab in Untreated MCL PatientsRecruitingNCT06463691Phase 2
• Irinotecan Hydrochloride Liposome Combined With Capecitabine and Lenvatinib in Patients With Biliary Tract CarcinomaNot yet recruitingNCT06463548Not applicable
• Study of SGR-3515 In Participants With Advanced Solid Tumors.RecruitingNCT06463340Phase 1
• Phase II Trial of Almonertinib Plus Lastet for EGFR+ Non-small Cell Lung CancerNot yet recruitingNCT06463171Phase 2
• Sapanisertib and Serabelisib (PIKTOR) With Paclitaxel and a Substudy With an Insulin-Suppressing Diet in Patients With Advanced/Recurrent Endometrial CancerRecruitingNCT06463028Phase 2
• Trametinib Plus Anlotinib Combined With Tislelizumab in KRAS-mutant NSCLCNot yet recruitingNCT06456138Phase 1/2
• Cadonilimab Combined With Regorafenib as A Third-line Treatment in Patients With MSS CRLMRecruitingNCT06455254Phase 2
• Orelabrutinib Combined With Obinutuzumab and Lenalidomide (OGL Regimen) as First-line Treatment for Marginal Zone Lymphoma.RecruitingNCT06454968Phase 2
• Adjuvant Adebrelimab Plus Apatinib for Participants With HCC at High-risk of Recurrence After Curative ResectionRecruitingNCT06454578Phase 2
• Efficacy of Upadacitinib After NECS in VitiligoRecruitingNCT06454461Not applicable
• A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic ArthritisRecruitingNCT06454188Phase 4
• TGRX-678 Chinese Phase II in Chronic Myelogenous Leukemia (CML) PatientsRecruitingNCT06453902Phase 2
• Gumarontinib Combined With 3rd EGFR-TKI in Patients With Non-small Cell Lung Cancer.Not yet recruitingNCT06452433Phase 2
• A Study to Learn More About How Well Sevabertinib Works and How Safe it is Compared With Standard Treatment, in Participants Who Have Advanced Non-small Cell Lung Cancer (NSCLC) With Mutations of the Human Epidermal Growth Factor Receptor 2 (HER2)RecruitingNCT06452277Phase 3
• A Study to Evaluate the Safety, Pharmacokinetics, and Pharmacokinetic of TQB3702 Tablets in Healthy Adult SubjectsRecruitingNCT06448273Phase 1
• Fruquintinib After ICIs Treatment in Unresectable Hepatocellular CarcinomaRecruitingNCT06446154Phase 2
• A Clinical Study Evaluating the Safety and Efficacy of ZRMT Regimen in the Treatment of PCNSLRecruitingNCT06445257Not applicable
• Toripalimab Plus Anlotinib for the Maintenance of Extensive Stage Small CellNot yet recruitingNCT06441344Phase 3
• Efficacy of Pola-RCHP-X vs Pola-RCHP in Untreated DLBCLNot yet recruitingNCT06441097Phase 2
• Vemurafenib and Cobimetinib for the Treatment of Patients With High Risk Differentiated Thyroid Carcinoma With BRAFV600E MutationRecruitingNCT06440850Phase 2
• Pembrolizumab Plus CA-4948 for the Treatment of Patients With Progressive Metastatic Urothelial Cancer Despite Prior ImmunotherapyRecruitingNCT06439836Phase 1
• The SAPPHO Study: Sequential Therapy With Curative Intent in de Novo HER2+ Metastatic Breast CancerRecruitingNCT06439693Phase 2
• Baricitinib for the Lung Injury Following Spontaneous SAHNot yet recruitingNCT06439615Phase 2
• Phase I/II Trial of Pemigatinib in Combination With Atezolizumab and Bevacizumab for Treatment of Advanced Cholangiocarcinoma With FGFR2 FusionRecruitingNCT06439485Phase 1/2
• 3T Therapy in the Treatment of MDA5-positive DermatomyositisEnrolling by invitationNCT06438679Phase 4
• An Exploratory Study of Efficacy and Safety of Iruplinalkib Tablets in Patients With ROS1 Positive Non-small Cell Lung CancerRecruitingNCT06436885Early Phase 1
• Osimertinib and Etoposide as First-Line Treatment in Osimertinib-Resistant Advanced EGFR-Mutant NSCLCNot yet recruitingNCT06436144Phase 2
• A Clinical Study of SPH5030 Tablets in the Treatment of Her2-positive/Mutated Biliary Tract OR Colorectal Cancer Patients.RecruitingNCT06434597Phase 2
• Tamoxifen and Pegylated Liposomal Doxorubicin for the Treatment of Patients With Metastatic or Inoperable, Locally Advanced Triple Negative Breast CancerRecruitingNCT06434064Phase 2
• Anlotinib Combined With Benmelstobart for Advanced PheochromocytomaNot yet recruitingNCT06429397Phase 2
• A Study to Evaluate the Risk of Tumor Lysis Syndrome (TLS) in Adult Participants Receiving Oral Venetoclax in Combination With Intravenously Infused Obinutuzumab or Oral Acalabrutinib for Previously Untreated Chronic Lymphocytic Leukemia (CLL)RecruitingNCT06428019Phase 3
• This is a Phase II, Open-label, Multicentre Study of Zanubrutinib-containing Regimens in Patients With Newly Diagnosed Mantle Cell LymphomaNot yet recruitingNCT06427213Phase 2
• Neoadjuvant Cadonilimab Combined With Anlotinib in Locally Advanced Resectable Esophageal Squamous Cell CarcinomaNot yet recruitingNCT06426797Phase 2
• Regorafenib in Combination With Multimodal Metronomic Chemotherapy for Chemo-resistant Metastatic Colorectal CancersRecruitingNCT06425133Phase 2
• A Trial of AK104 or AK112 in Combination With Axitinib in Patients With Metastatic Mucosal MelanomaEnrolling by invitationNCT06424626Phase 1
• Fruquintinib Plus Camrelizumab and HAIC in the Treatment of Non-MSI-H Advanced Colorectal CancerNot yet recruitingNCT06423937Phase 2
• Linperlisib Combined With Chidamide in Patients With PTCLRecruitingNCT06421948Phase 1/2
• Neoadjuvant Therapy in Patients With Resectable HCC Screened by a Multimodal Deep Learning ModelRecruitingNCT06420440Phase 2
• Adebrelimab Plus Apatinib and Etoposide for the Treatment of HER2-Negative Breast Cancer Brain MetastasisRecruitingNCT06418594Phase 2
• Lenvatinib and Adebrelimab Combined With GEMOX in the Perioperative Treatment of Potentially Resectable Intrahepatic CholangiocarcinomaNot yet recruitingNCT06417606Phase 4
• A Study of Paclitaxel Combined With Apatinib and Adebrelimab in Gastric/Gastroesophageal Junction AdenocarcinomaRecruitingNCT06415669Phase 2
• Surufatinib Combined With Tislelizumab in Advanced Lung Cancer With Neuroendocrine DifferentiationNot yet recruitingNCT06414915Phase 2
• Combination of Tagraxofusp With Pacritinib in Patients With Intermediate-1 or Higher Myelofibrosis, Who Have Had Prior Therapy With the Approved JAK Inhibitors or in Which Therapy With the Approved JAK Inhibitors is Not Appropriate, Contraindicated or DeclinedRecruitingNCT06414681Early Phase 1
• Ulixertinib in People With Histiocytic NeoplasmsRecruitingNCT06411821Phase 2
• Combination Therapy for BRAF-V600E Metastatic CRCmRecruitingNCT06411600Phase 2
• PEARL Study: PotEntial of Asciminib in the eaRly Treatment of CMLRecruitingNCT06409936Phase 2
• FOLFOX Plus Lenvatinib Adjuvant Therapy for Hepatocellular Carcinoma Post-Liver TransplantationNot yet recruitingNCT06409637Phase 1/2
• Sequential Therapies Modeled on Evolutionary Dynamics for Breast CancerRecruitingNCT06409390Phase 2
• A Trial to Study the Safety and Efficacy of SM-020 Gel 1.0% in Subjects With Seborrheic Keratoses and Non-Melanoma Skin CancersRecruitingNCT06409195Phase 2
• A Phase II Clinical Study of Cadonilimab in Treatment-naïve or Relapsed Extensive Small Cell Lung CancerRecruitingNCT06406673Phase 2
• Cadonilimab in Combination With Lenvatinib and Hepatic Arterial Infusion Chemotherapy (HAIC) for the Treatment of Unresectable Hepatocellular CarcinomaRecruitingNCT06406634Phase 2
• A Phase I Study of Decitabine, Lisaftoclax, and Olverembatinib in Patients With Advanced Chronic Myeloid Leukemia and Philadelphia Chromosome-Positive Acute Myeloid LeukemiaRecruitingNCT06401603Phase 1
• A Study of Avutometinib, Defactinib, and Letrozole in People With Low-Grade Serous Ovarian CancerRecruitingNCT06394804Phase 2
• High-dose Furmonertinib in the Treatment in Patients With Advanced, Metastatic NSCLC With Progressed After First- or Second-line Treatment With OsimertinibRecruitingNCT06394674Phase 2
• Pirtobrutinib in Combination With Rituximab in Adults With Untreated Marginal Zone Lymphoma (PIONEER-MZL)RecruitingNCT06390956Phase 2
• Adding Dasatinib Or Venetoclax To Improve Responses In Children With Newly Diagnosed T-Cell Acute Lymphoblastic Leukemia (ALL) Or Lymphoma (T-LLY) Or Mixed Phenotype Acute Leukemia (MPAL)RecruitingNCT06390319Phase 2
• A Phase 2, Open Label Study of PEmigatinib and REtifanlimab in Advanced Dedifferentiated LIposarcoma (PERELI)RecruitingNCT06389799Phase 2
• HAIC+Adebrelimab+Lenvatinib for Conversion Treatment of Potentially Resectable, Locally Advanced Biliary Tract CancerNot yet recruitingNCT06389500Phase 2

← Protein Kinase Inhibitors overview